Array BioPharma Inc. (NASDAQ:ARRY) was down -2.32% at $7.99 on Friday, in a 52-week range of $3.10 to $13.40 and with a consensus analyst target price of $12.33. As for the mean price target, it implies upside of 50.73% from the $8.18 prior closing price. Array BioPharma Inc. has a 1.29B market cap and its past year revenues were 160.30M. Going from the most negative analyst price target to above consensus is one thing. Now Array BioPharma Inc.’s current price is $7.01 shy of the official highest sell-side analyst price target on Wall Street.
Array BioPharma Inc. (NASDAQ:ARRY) has declined -9.10% since January and is down -2.08% for the past week. The share price of ARRY has increased by over 0.88% in the last six months. This increase is typical for the uptrend and shows the considerable optimism among investors.
A look at some of the inputs to technical analysis model shows how Array BioPharma Inc. current price compares to its recent moving averages. Array BioPharma Inc. is currently trading 0.03% above its 20-day and -0.25% versus the 200-day simple moving averages while -4.09% compared with its 50-day simple moving average. Additionally, Array BioPharma Inc. (ARRY) stock price has gone up by 8.71% over the last 20 trading days, and its price is -40.37% below the 52-week high.
For a total return analysis, there is the -108.50% return on equity to consider. According to the past 12 months report, the income was almost $-112.20M and sales remained $160.30M. Its price to sales ratio of 8.72 ranks lower than the industry’s 104.98. Its price/book multiple of 50.15 compared with the 15.32 while its free cash flow yield should be matched with that of its industry’s 94.53.
The Average True Range indicator applied to a daily chart of Apple has a current ATR reading of 0.51. This gives traders an indication of how much volatility or movement they can expect each day. Average True Range looks at the distance the price is traveling each day and plots it on a graph. The ATR reading can then be used by traders to determine when markets are most likely to range, when there is a high interest in a trend, or when extreme levels are being reached indicating a reversal.
Radian Group Inc. (NYSE:RDN) shares were last seen down -2.33% at $15.91, which is 27.81% higher than the previous trading session. The 52-week range is $9.29 to $19.87 and the consensus target price is $20.82. The company has a market cap of $3.45B and its 12 month revenue was almost $1.21B. The stock has been downbeat for quite some time as is down -5.30% for the last 20 trading days, and now the firm’s performance is turning out to be bearish with a -3.87% fall for the week. It has gain by over 33.70% in the last twelve months.
Going from the most bullish analyst price target to below consensus is one thing. Now Radian Group Inc. $20.82 target price is just $4.18 shy of the official lowest sell-side analyst price target on Wall Street. It looks like analysts are feeling bullish about the stock with overall sell-side analysts calling it a not a Buy. Their price objective ranges between $18.00 and $25.00.
For a profitability analysis, there is 26.20% net margin to consider. According to the past 5 years report, the company on average reported -9.80% year-over-year EPS growth and sales growth was recorded at -8.70%. Its forward price to earnings ratio of 11.50 ranks lower than the industry’s 12.34.